PROCEPT BioRobotics: Legacy Account Weakness Either Bottomed or Became the New Baseline

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

PRCT reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full reaction to the actual numbers.

PRCT exhibits highly volatile post-earnings price action with an average absolute Day 0 move of 7.08% and Day +1 move of 8.72%. The Day +1 range averages 12.94%, indicating substantial intraday volatility as investors digest results.

The most extreme reaction came in October 2024, when the stock surged 32.33% on Day 0 and added another 6.25% on Day +1—a massive two-day gain that likely reflected a significant positive surprise or strategic announcement. More recently, reactions have been predominantly negative: the February 2026 report saw a modest 2.13% Day 0 gain followed by a brutal 15.12% Day +1 decline, while November 2025 delivered a 9.74% Day +1 drop despite a small initial gain.

The most recent report in August 2026 showed relatively muted movement with just a 0.54% Day 0 decline and 5.80% Day +1 gain, suggesting the market may have already priced in modest disappointment. However, the wide historical range—from double-digit gains to double-digit losses—means investors should prepare for significant volatility regardless of whether results beat or miss expectations.

Part 2.2: Options Market Expected Move

The options market is pricing in no expected move for the November expiration (0.00%), which appears to be a data anomaly given PRCT's historical volatility. Based on the stock's actual earnings behavior—averaging 7.08% on Day 0 and 8.72% on Day +1—investors should anticipate meaningful post-earnings movement despite the options data suggesting otherwise.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on PRCT with an average rating of 3.56 (between Hold and Buy) and a mean price target of $22.33, implying 10.7% upside from the current $20.17 price. The consensus reflects divided opinion: 5 Strong Buys and 10 Holds are offset by 1 Moderate Sell, with no Strong Sells in the mix.

Sentiment has improved over the past month, with Strong Buys increasing from 4 to 5 while Holds and Sells remained stable. This modest upgrade suggests some analysts see value emerging despite recent execution challenges. The price target range is wide—from a low of $16.00 to a high of $30.00—reflecting significant disagreement about PRCT's near-term prospects and the company's ability to resolve utilization issues at legacy accounts.

The recent Barclays initiation at Overweight with a $30 price target (the high end of the range) provides a bullish counterpoint to the more cautious consensus. However, with the mean target of $22.33 representing only modest upside, the analyst community appears to be taking a wait-and-see approach, likely wanting evidence of stabilizing procedure volumes and improved visibility before becoming more aggressive.

Part 4: Technical Picture

PRCT enters earnings with improving but still cautious technical momentum. The Barchart Technical Opinion currently shows a 40% Sell signal, a notable improvement from 64% Sell one week ago and 100% Sell one month ago, indicating the stock has been gradually recovering from oversold conditions.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal suggests near-term momentum remains tentative despite recent improvement
• Medium-term (50% Sell): Neutral-to-negative reading indicates the intermediate trend has not yet turned decisively positive
• Long-term (50% Sell): Moderate sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak in strength and Weakest in direction, suggesting PRCT lacks conviction in either direction heading into the earnings event and remains vulnerable to sharp moves on the results.

The stock is trading at $20.17, positioned above its 5-day ($19.86), 10-day ($19.72), 20-day ($19.02), and 50-day ($19.33) moving averages, indicating short-term momentum has turned positive. However, it remains above the 100-day average ($19.91) by a slim margin and notably below the 200-day moving average of $23.22, confirming the longer-term downtrend remains intact.

The technical setup heading into earnings is mixed with a slight positive bias. While the stock has reclaimed its short-term moving averages and the Barchart Opinion has improved significantly from extreme oversold levels, the failure to reclaim the 200-day moving average and the weak trend characteristics suggest limited technical support. The 13% gap between the current price and the 200-day average represents a key resistance zone that would require a strong earnings beat to overcome. Given the stock's history of volatile post-earnings moves and its current position in no-man's land between short-term support and long-term resistance, traders should expect heightened risk in either direction.